Gestational diabetes & diabetes in pregnancy
HbA1c improvement in pregnant women with type 1 diabetes using the CamAPS FX automated insulin delivery ( automated insulin delivery (AID) ) system: Clinical and economic outcomes
Main finding · Projected clinical outcomes and costs with 3.3 mmol/mol (0.3%) HbA1c reductionResult — go to the resultIncremental cost difference per woman -£1016Authors' conclusion
CamAPS FX AID improves third-trimester HbA1c with projected cost reductions for the UK healthcare system.
Study context
- Population
- Pregnant women with T1D (AiDAPT trial data); third-trimester HbA1c categories <42, 42–53, ≥53 mmol/mol
- Comparison
- CamAPS FX AID vs Standard Care
- Outcome
- Projected clinical outcomes and costs with 3.3 mmol/mol (0.3%) HbA1c reduction
- Follow-up
- Third trimester
Methodological detailsbased on AiDAPT trial data, UK NHS perspective, UK-specific healthcare costs from NHS National Schedule and other published sources
- Based on AiDAPT trial data
- UK NHS perspective
- UK-specific healthcare costs from NHS National Schedule and other published sources
Main finding
As reported in the abstract
Incremental cost difference per woman
-£1016
- Projected reduction in pre-eclampsia risk
- −13%
- Projected reduction in high dependency neonatal care days
- −16%
- Projected reduction in neonatal ICU days
- −12%
- Projected cost reduction for the NHS, conservative assumptions
- £6,696,636
- Cost saving in simulations
- 96.8%
Original publication
HbA1c improvement in pregnant women with type 1 diabetes using the CamAPS FX automated insulin delivery ( AID ) system: Clinical and economic outcomes. Diabet Med. Published 21 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →